Skip to main
FGEN
FGEN logo

FibroGen (FGEN) Stock Forecast & Price Target

FibroGen (FGEN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 31%
Hold 38%
Sell 8%
Strong Sell 8%

Bulls say

FibroGen Inc. is focused on advancing its R&D pipeline with significant revenue generated from collaboration agreements, primarily in Europe and Japan. The anticipated extension of the company's cash runway, bolstered by a recent $75 million cash injection from the sale of FibroGen China to AstraZeneca, supports its financial health amid challenging market conditions. Additionally, the potential for FG-3246 to demonstrate a rPFS benefit of 12 months or more positions the company favorably against competitors, enhancing its prospects for becoming a market leader in therapeutics for serious medical conditions.

Bears say

FibroGen Inc. faces significant challenges that could negatively impact its stock performance, primarily stemming from the risks associated with clinical trials, which could yield failed or inconclusive results. Additionally, the company's reliance on collaboration agreements for revenue generation raises concerns about its ability to secure adequate funding necessary for product development, potentially leading to dilutive capital raises. Compounding these issues is the risk of lack of commercial success for its therapeutics and the threat of delisting, which could further undermine investor confidence.

FibroGen (FGEN) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 31% recommend Buy, 38% suggest Holding, 8% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About FibroGen (FGEN) Forecast

Analysts have given FibroGen (FGEN) a Hold based on their latest research and market trends.

According to 13 analysts, FibroGen (FGEN) has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

FibroGen (FGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.